Concise Postsynthetic Preparation of Oligonucleotide–Oligopeptide Conjugates Through Facile Disulfide Bond Formation

References

• Burnett JC , RossiJJ. RNA-based therapeutics: current progress and future prospects. Chem. Biol.19 (1), 60–71 (2012).
   PubMed Web of Science ®Google Scholar
• Parhofer KG . Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid.7, 29–38 (2012).
   PubMedGoogle Scholar
• Scully MA , PandyaS, MoxleyRT. Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy. Expert Opin. Orphan Drugs1 (1), 33–46 (2013).
   Web of Science ®Google Scholar
• Coelho T , AdamsD, SilvaAet al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med.369 (9), 819–829 (2013).
   PubMed Web of Science ®Google Scholar
• Dirin M , WinklerJ. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin. Biol. Ther.13 (6), 875–888 (2013).
   PubMed Web of Science ®Google Scholar
• Yamamoto T , NakataniM, NarukawaK, ObikaS. Antisense drug discovery and development. Future Med. Chem.3 (3), 339–365 (2011).
   PubMed Web of Science ®Google Scholar
• Bennett CF , SwayzeEE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol.50, 259–293 (2010).
   PubMed Web of Science ®Google Scholar
• Akdim F , StroesESG, SijbrandsEJGet al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol.55 (15), 1611–1618 (2010).
   PubMed Web of Science ®Google Scholar
• Anderson EM , MillerP, IlsleyDet al. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther.13 (4), 406–414 (2006).
   PubMed Web of Science ®Google Scholar
• Stessl M , Marchetti-DeschmannM, WinklerJ, LachmannB, AllmaierG, NoeCR. A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. J. Proteomics72 (6), 1019–1030 (2009).
   PubMed Web of Science ®Google Scholar
• Winkler J , StesslM, AmarteyJ, NoeCR. Off-target effects related to the phosphorothioate modification of nucleic acids. ChemMedChem.5 (8), 1344–1352 (2010).
   PubMed Web of Science ®Google Scholar
• Stessl M , NoeCR, WinklerJ. Off-target effects and safety aspects of phosphorothioate oligonucleotides. In : From Nucleic Acids Sequences to Molecular Medicine, RNA Technologies. ErdmannVA, BarciszewskiJ. ( Eds.). Springer Verlag, Berlin, Germany, 67–83 (2012).
   Google Scholar
• Stein CA , HansenJB, LaiJet al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res.38 (1), e3 (2010).
   PubMed Web of Science ®Google Scholar
• Winkler J . Oligonucleotide conjugates for therapeutic applications. Ther. Deliv.4 (7), 791–809 (2013).
   PubMedGoogle Scholar
• Gagnon KT , WattsJK. 10th Annual Meeting of the Oligonucleotide Therapeutics Society. Nucl. Acids Therap.24 (6), 428–434 (2014).
   Web of Science ®Google Scholar
• Prakash TP , GrahamMJ, YuJet al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res.42 (13), 8796–8807 (2014).
   PubMed Web of Science ®Google Scholar
• Nair JK , WilloughbyJLS, ChanAet al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc.136 (49), 16958–16961 (2014).
   PubMed Web of Science ®Google Scholar
• Rajeev KG , NairJK, JayaramanMet al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. ChemBioChem.16 (6), 903–908 (2015).
   PubMed Web of Science ®Google Scholar
• Jarver P , MagerI, LangelU. In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol. Sci.31 (11), 528–535 (2010).
   PubMed Web of Science ®Google Scholar
• Ezzat K , AndaloussiSE, ZaghloulEMet al. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res.39 (12), 5284–5298 (2011).
   PubMed Web of Science ®Google Scholar
• Park TG , JeongJH, KimSW. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev.58 (4), 467–486 (2006).
   PubMed Web of Science ®Google Scholar
• Winkler J , UrbanE, NoeCR. Oligonucleotides conjugated to short lysine chains. Bioconjug. Chem.16 (4), 1038–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Chen C-P , ZhangL-R, PengX-B, WangS-Q, ZhangL-H. A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide. Bioconjug. Chem.14 (3), 532–538 (2003).
   PubMed Web of Science ®Google Scholar
• Lonnberg H . Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics. Bioconjug. Chem.20 (6), 1065–1094 (2009).
   PubMed Web of Science ®Google Scholar
• Douglas ME , BeijerB, SproatBS. An approach towards thiol mediated labelling in the minor groove of oligonucleotides. Bioorg. Med. Chem. Lett.4 (8), 995–1000 (1994).
   Web of Science ®Google Scholar
• Jin S , MiduturuCV, McKinneyDC, SilvermanSK. Synthesis of amine- and thiol-modified nucleoside phosphoramidites for site-specific introduction of biophysical probes into RNA. J. Org. Chem.70 (11), 4284–4299 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner E , OberhauserB, HolznerAet al. A simple procedure for the preparation of protected 2′-O-methyl- or 2′-O-ethylribonucleoside 3′-O-phosphoramidites. Nucleic Acids Res.19 (21), 5965–5971 (1991).
   PubMed Web of Science ®Google Scholar
• Hamm ML , PiccirilliJA. Incorporation of 2′-deoxy-2′-mercaptocytidine into oligonucleotides via phosphoramidite chemistry. J. Org. Chem.62 (10), 3415–3420 (1997).
   PubMed Web of Science ®Google Scholar
• Juliano RL . Peptide–oligonucleotide conjugates for the delivery of antisense and siRNA. Curr. Opin. Mol. Therap.7 (2), 132–136 (2005).
   PubMedGoogle Scholar
• Astriab-Fisher A , SergueevDS, FisherM, Ramsay ShawB, JulianoRL. Antisense inhibition of P-glycoprotein expression using peptide–oligonucleotide conjugates. Biochem. Pharmacol.60 (1), 83–90 (2000).
   PubMed Web of Science ®Google Scholar
• Venkatesan N , KimBH. Peptide conjugates of oligonucleotides: synthesis and applications. Chem. Rev., 106 (9), 3712–3761 (2006).
   PubMed Web of Science ®Google Scholar
• Lu K , DuanQ-P, MaL, ZhaoD-X. Chemical strategies for the synthesis of peptide−oligonucleotide conjugates. Bioconjug. Chem.21 (2), 187–202 (2010).
   PubMed Web of Science ®Google Scholar
• Stetsenko DA , GaitMJ. efficient conjugation of peptides to oligonucleotides by ‘native ligation’. J. Org. Chem.65 (16), 4900–4908 (2000).
   PubMed Web of Science ®Google Scholar
• Wackerbarth H , MarieR, GrubbMet al. Thiol- and disulfide-modified oligonucleotide monolayer structures on polycrystalline and single-crystal Au(111) surfaces. J. Solid State Electrochem.8 (7), 474–481 (2004).
   Web of Science ®Google Scholar
• Maurel F , DebartF, CavelierFet al. Toward high yield synthesis of peptide–oligonucleotide chimera through a disulfide bridge: a simplified method for oligonucleotide activation. Bioorg. Med. Chem. Lett.15 (22), 5084–5087 (2005).
   PubMed Web of Science ®Google Scholar
• Winkler J , UrbanE, LosertD, WacheckV, PehambergerH, NoeCR. A novel concept for ligand attachment to oligonucleotides via a 2′-succinyl linker. Nucleic Acids Res.32 (2), 710–718 (2004).
   PubMed Web of Science ®Google Scholar
• Lai JC , BenimetskayaL, KhvorovaAet al. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Mol. Cancer Ther.4 (2), 305–315. (2005).
   PubMed Web of Science ®Google Scholar
• Lai JC , TanW, BenimetskayaL, MillerP, ColombiniM, SteinCA. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc. Natl Acad. Sci. USA.103 (19), 7494–7499 (2006).
   PubMed Web of Science ®Google Scholar
• Tan W , LokeY-H, SteinCA, MillerP, ColombiniM. Phosphorothioate oligonucleotides block the VDAC channel. Biophys. J.93 (4), 1184–1191 (2007).
   PubMed Web of Science ®Google Scholar
• Opar A . Exon-skipping drug pulls ahead in muscular dystrophy field. Nat. Med.18 (9), 1314 (2012).
   PubMed Web of Science ®Google Scholar
• Wooddell CI , RozemaDB, HossbachMet al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther.21 (5), 973–985 (2013).
   PubMed Web of Science ®Google Scholar
• Ricotta DN , FrishmanW. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol. Rev.20 (2), 90–95 (2012).
   PubMed Web of Science ®Google Scholar
• Lorenzer C , DirinM, WinklerA-M, BaumannV, WinklerJ. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J. Control. Release.203 (1), 1–15 (2015).
   PubMedGoogle Scholar
• Sjouke B , BalakDMW, BeuersU, RatziuV, StroesESG. Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr. Opin. Lipidol.24 (4), 301–306 (2013).
   PubMed Web of Science ®Google Scholar
• Semple SC , AkincA, ChenJet al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol.28 (2), 172–176 (2010).
   PubMed Web of Science ®Google Scholar
• Winkler J . Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther. Deliv.2 (7), 891–905 (2011).
   PubMedGoogle Scholar